A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-negative Inflammatory Breast Cancer (IBC)

Trial Profile

A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-negative Inflammatory Breast Cancer (IBC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Inflammatory breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 02 Feb 2018 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
    • 24 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top